Digital tools for the assessment of pharmacological treatment for depressive disorder: State of the art

Evelien Van Assche; J. Antoni Ramos-Quiroga; Carmine M. Pariante; Luca Sforzini; Allan H. Young; Yanina Flossbach; Stefan M. Gold; Witte J.G. Hoogendijk; Bernhard T. Baune; Eduard Maron

doi:10.1016/j.euroneuro.2022.05.007

Digital tools for the assessment of pharmacological treatment for depressive disorder: State of the art

Evelien Van Assche^*, J. Antoni Ramos-Quiroga, Carmine M. Pariante, Luca Sforzini, Allan H. Young, Yanina Flossbach, Stefan M. Gold, Witte J.G. Hoogendijk, Bernhard T. Baune, Eduard Maron

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

10 Citations (Scopus)

Abstract

Depression is an invalidating disorder, marked by phenotypic heterogeneity. Clinical assessments for treatment adjustments and data-collection for pharmacological research often rely on subjective representations of functioning. Better phenotyping through digital applications may add unseen information and facilitate disentangling the clinical characteristics and impact of depression and its pharmacological treatment in everyday life. Researchers, physicians, and patients benefit from well-understood digital phenotyping approaches to assess the treatment efficacy and side-effects. This review discusses the current possibilities and pitfalls of wearables and technology for the assessment of the pharmacological treatment of depression. Their applications in the whole spectrum of treatment for depression, including diagnosis, treatment of an episode, and monitoring of relapse risk and prevention are discussed. Multiple aspects are to be considered, including concerns that come with collecting sensitive data and health recordings. Also, privacy and trust are addressed. Available applications range from questionnaire-like apps to objective assessment of behavioural patterns and promises in handling suicidality. Nonetheless, interpretation and integration of this high-resolution information with other phenotyping levels, remains challenging. This review provides a state-of-the-art description of wearables and technology in digital phenotyping for monitoring pharmacological treatment in depression, focusing on the challenges and opportunities of its application in clinical trials and research.

Original language	English
Pages (from-to)	100-116
Number of pages	17
Journal	European Neuropsychopharmacology
Volume	60
DOIs	https://doi.org/10.1016/j.euroneuro.2022.05.007
Publication status	Published - Jul 2022

Keywords

Depression
Diagnosis
Digital phenotyping
Monitoring
Prevention
Wearables

Access to Document

10.1016/j.euroneuro.2022.05.007

Cite this

Van Assche, E., Antoni Ramos-Quiroga, J., Pariante, C. M., Sforzini, L., Young, A. H., Flossbach, Y., Gold, S. M., Hoogendijk, W. J. G., Baune, B. T., & Maron, E. (2022). Digital tools for the assessment of pharmacological treatment for depressive disorder: State of the art. European Neuropsychopharmacology, 60, 100-116. https://doi.org/10.1016/j.euroneuro.2022.05.007

@article{87b8e5ac636d453dac3372d2368ae0c8,

title = "Digital tools for the assessment of pharmacological treatment for depressive disorder: State of the art",

abstract = "Depression is an invalidating disorder, marked by phenotypic heterogeneity. Clinical assessments for treatment adjustments and data-collection for pharmacological research often rely on subjective representations of functioning. Better phenotyping through digital applications may add unseen information and facilitate disentangling the clinical characteristics and impact of depression and its pharmacological treatment in everyday life. Researchers, physicians, and patients benefit from well-understood digital phenotyping approaches to assess the treatment efficacy and side-effects. This review discusses the current possibilities and pitfalls of wearables and technology for the assessment of the pharmacological treatment of depression. Their applications in the whole spectrum of treatment for depression, including diagnosis, treatment of an episode, and monitoring of relapse risk and prevention are discussed. Multiple aspects are to be considered, including concerns that come with collecting sensitive data and health recordings. Also, privacy and trust are addressed. Available applications range from questionnaire-like apps to objective assessment of behavioural patterns and promises in handling suicidality. Nonetheless, interpretation and integration of this high-resolution information with other phenotyping levels, remains challenging. This review provides a state-of-the-art description of wearables and technology in digital phenotyping for monitoring pharmacological treatment in depression, focusing on the challenges and opportunities of its application in clinical trials and research.",

keywords = "Depression, Diagnosis, Digital phenotyping, Monitoring, Prevention, Wearables",

author = "{Van Assche}, Evelien and {Antoni Ramos-Quiroga}, J. and Pariante, {Carmine M.} and Luca Sforzini and Young, {Allan H.} and Yanina Flossbach and Gold, {Stefan M.} and Hoogendijk, {Witte J.G.} and Baune, {Bernhard T.} and Eduard Maron",

note = "Funding Information: The presented work is part of the ECNP Network Pharmacogenomics and Transcriptomics which is supported by the European College of Neuropsychopharmacology (ECNP). Publisher Copyright: {\textcopyright} 2022",

year = "2022",

month = jul,

doi = "10.1016/j.euroneuro.2022.05.007",

language = "English",

volume = "60",

pages = "100--116",

journal = "European Neuropsychopharmacology",

issn = "0924-977X",

publisher = "Elsevier",

}

TY - JOUR

T1 - Digital tools for the assessment of pharmacological treatment for depressive disorder

T2 - State of the art

AU - Van Assche, Evelien

AU - Antoni Ramos-Quiroga, J.

AU - Pariante, Carmine M.

AU - Sforzini, Luca

AU - Young, Allan H.

AU - Flossbach, Yanina

AU - Gold, Stefan M.

AU - Hoogendijk, Witte J.G.

AU - Baune, Bernhard T.

AU - Maron, Eduard

N1 - Funding Information: The presented work is part of the ECNP Network Pharmacogenomics and Transcriptomics which is supported by the European College of Neuropsychopharmacology (ECNP). Publisher Copyright: © 2022

PY - 2022/7

Y1 - 2022/7

N2 - Depression is an invalidating disorder, marked by phenotypic heterogeneity. Clinical assessments for treatment adjustments and data-collection for pharmacological research often rely on subjective representations of functioning. Better phenotyping through digital applications may add unseen information and facilitate disentangling the clinical characteristics and impact of depression and its pharmacological treatment in everyday life. Researchers, physicians, and patients benefit from well-understood digital phenotyping approaches to assess the treatment efficacy and side-effects. This review discusses the current possibilities and pitfalls of wearables and technology for the assessment of the pharmacological treatment of depression. Their applications in the whole spectrum of treatment for depression, including diagnosis, treatment of an episode, and monitoring of relapse risk and prevention are discussed. Multiple aspects are to be considered, including concerns that come with collecting sensitive data and health recordings. Also, privacy and trust are addressed. Available applications range from questionnaire-like apps to objective assessment of behavioural patterns and promises in handling suicidality. Nonetheless, interpretation and integration of this high-resolution information with other phenotyping levels, remains challenging. This review provides a state-of-the-art description of wearables and technology in digital phenotyping for monitoring pharmacological treatment in depression, focusing on the challenges and opportunities of its application in clinical trials and research.

AB - Depression is an invalidating disorder, marked by phenotypic heterogeneity. Clinical assessments for treatment adjustments and data-collection for pharmacological research often rely on subjective representations of functioning. Better phenotyping through digital applications may add unseen information and facilitate disentangling the clinical characteristics and impact of depression and its pharmacological treatment in everyday life. Researchers, physicians, and patients benefit from well-understood digital phenotyping approaches to assess the treatment efficacy and side-effects. This review discusses the current possibilities and pitfalls of wearables and technology for the assessment of the pharmacological treatment of depression. Their applications in the whole spectrum of treatment for depression, including diagnosis, treatment of an episode, and monitoring of relapse risk and prevention are discussed. Multiple aspects are to be considered, including concerns that come with collecting sensitive data and health recordings. Also, privacy and trust are addressed. Available applications range from questionnaire-like apps to objective assessment of behavioural patterns and promises in handling suicidality. Nonetheless, interpretation and integration of this high-resolution information with other phenotyping levels, remains challenging. This review provides a state-of-the-art description of wearables and technology in digital phenotyping for monitoring pharmacological treatment in depression, focusing on the challenges and opportunities of its application in clinical trials and research.

KW - Depression

KW - Diagnosis

KW - Digital phenotyping

KW - Monitoring

KW - Prevention

KW - Wearables

UR - http://www.scopus.com/inward/record.url?scp=85131454030&partnerID=8YFLogxK

U2 - 10.1016/j.euroneuro.2022.05.007

DO - 10.1016/j.euroneuro.2022.05.007

M3 - Review article

AN - SCOPUS:85131454030

SN - 0924-977X

VL - 60

SP - 100

EP - 116

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

ER -

Digital tools for the assessment of pharmacological treatment for depressive disorder: State of the art

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this